Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


UK Medtech Industry Advances Its Case For US FTA Amid Ongoing EU Talks

Executive Summary

Securing a favorable post-Brexit free trade agreement with the US is the principal aim of the UK’s Department for International Trade, and the UK medtech industry is pressing its case for closer business links with its largest non-EU trading partner.

You may also be interested in...

UK Medtech Gets A Role In Post-Brexit Trade Deal Negotiations

With the Brexit implementation period ending in four months, the UK government has launched a trade advisory group for international life sciences deal talks and given UK medtech a seat at the table.

A Global Approach To Medtech Regulation: The Post-EU Way Ahead For UK Industry?

As the UK looks to its future healthtech regulatory model after Brexit, the ABHI’s regulatory director Phil Brown suggests a system whereby the same product data can be used as the basis for entry not only to the EU, but also to global markets.

UK Medtech's US Innovation Hub Aims To Accentuate The Positive In Post-Brexit Phase

With Brexit moving ever closer, the UK medtech industry is trying to ensure that local manufacturers have a range of commercial options in overseas markets in the post-EU phase. The ABHI is playing a strong support role in this area, following up its recent international growth plan with a new US innovation hub, designed to offer outward-looking UK medtechs the tools to build positions in the world's largest market.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts